Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes.

@article{Blonde2006InterimAO,
  title={Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes.},
  author={Lawrence Blonde and Eric John Klein and Jenny Han and Bei Zhang and Susanna M Mac and Terri H Poon and Kristin Leigh Taylor and Michael E. Trautmann and Dennis Dong-Won Kim and David M. Kendall},
  journal={Diabetes, obesity & metabolism},
  year={2006},
  volume={8 4},
  pages={
          436-47
        }
}
AIM Exenatide, an incretin mimetic for the adjunct treatment of type 2 diabetes (DM2), reduced A1C and weight in 30-week placebo-controlled trials. This analysis examined the effects of exenatide on glycaemic control and weight over an 82-week period in patients with DM2 unable to achieve adequate glycaemic control with sulphonylurea (SU) and/or metformin (MET). METHODS This interim analysis is of 314 patients who received exenatide in the 30-week placebo-controlled trials and subsequently in… CONTINUE READING
BETA

Citations

Publications citing this paper.
SHOWING 1-10 OF 190 CITATIONS, ESTIMATED 42% COVERAGE

Cardiovascular biology of the incretin system.

  • Endocrine reviews
  • 2012
VIEW 15 EXCERPTS
CITES RESULTS
HIGHLY INFLUENCED

A review of exenatide as adjunctive therapy in patients with type 2 diabetes

  • Drug design, development and therapy
  • 2009
VIEW 9 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

Diabetes and obesity: therapeutic targeting and risk reduction - a complex interplay.

  • Diabetes, obesity & metabolism
  • 2010
VIEW 4 EXCERPTS
CITES BACKGROUND & METHODS
HIGHLY INFLUENCED

Targeting Incretins in Type 2 Diabetes: Role of GLP-1 Receptor Agonists and DPP-4 Inhibitors.

  • The review of diabetic studies : RDS
  • 2008
VIEW 8 EXCERPTS
CITES BACKGROUND & RESULTS
HIGHLY INFLUENCED

Evolution of Exenatide as a Diabetes Therapeutic

VIEW 7 EXCERPTS
CITES BACKGROUND & METHODS
HIGHLY INFLUENCED

Differentiating among incretin-based therapies in the management of patients with type 2 diabetes mellitus

  • Diabetology & Metabolic Syndrome
  • 2012
VIEW 7 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

FILTER CITATIONS BY YEAR

2004
2019

CITATION STATISTICS

  • 14 Highly Influenced Citations

Similar Papers

Loading similar papers…